Skip to main content
Press Enter
BASF offers the world's largest portfolio of chemical raw materials for the pharmaceutical industry, ensuring the needs of our partners are always met. Every step of biopharmaceutical manufacturing requires high-quality raw materials delivered through a transparent, sustainable supply chain. BASF Biopharma Ingredients is committed to meeting your requirements for every ingredient we supply to the biologics industry. At BASF, we create excipients that are safe, effective, and convenient for your customers. Whether you’re developing orally disintegrating formulations that require taste-masking or modified release tablets, BASF has ingredients to deliver the precision you need, every time. At BASF, we offer a comprehensive range of cutting-edge solubilization polymers, and have an unparalleled understanding of the corresponding process technologies. BASF offers an unparalleled portfolio of excipients for topical formulations, enabling you with the tools to overcome formulation challenges. With products based on over 150 years of industry experience, BASF is committed to maintaining the highest level of quality across the product spectrum. BASF offers a broad portfolio of chemistries designed to simplify the product development process. Coating polymers are suitable for a variety of oral formulation challenges. As multifunctional excipients, ethoxylated solubilizers are known for their utility across a large range of dosage form classes. BASF's pharma grade lipid-based excipients are manufactured in GMP-compliant facilities with high quality and reliability in mind. BASF's portfolio of poloxamers are renown for their best-in-class quality. Consisting of a broad portfolio of polyethylene glycols (PEGs), BASF's portfolio of ethoxylated polymer-solubilizers is known for its versatility across a myriad of dosage forms. BASF offers a broad portfolio of functional excipients including our pharmaceutical grade polysorbate and sorbitan esters. Povidones, copovidones, and crospovidones are versatile materials that serve as the foundation of oral solid dosage forms. BASF's portfolio of solvents and co-solvents are suitable for a wide range of applications and processing methodologies. BASF offers a broad portfolio of brand families that are suitable for oral, topical, parenteral, and biologic applications. Coprocessed excipients are combination, all-in-one solutions. Kollicoat® coating polymers are suitable for a variety of oral formulation challenges. Kollicream® pharma grade solvents and emollients are manufactured in GMP-compliant facilities with high quality and reliability in mind. Kollidon® povidones, copovidones, and crospovidones are versatile materials that are most commonly used for solid oral dosage forms. Kolliphor® solubilizers, emulsifiers, co-emulsifiers, and surfactants enable the development of safe and effective formulations. Kollisolv® solubilizers and solvents are suitable for a wide range of applications and processing methodologies. Kolliwax® structuring agents, moisture barriers, and lubricants enable the formulation of various dosage forms. Novata® hard fats are structuring agents and matrix builders. Soluplus® is a novel solubilizer, crystallization inhibitor, and a matrix forming polymer. Explore this collection of resources to learn more about our innovative research and pharma solutions.
  • The collaboration brings a seamless digital experience to more formulators worldwide
  • The first phase will make IFF’s leading product brands Avicel® and Ac-Di-Sol® available to users in ZoomLab™
  • Users can find IFF ingredients in ZoomLab™ Excipient Database and throughout the different ZoomLab™ modules

Florham Park, New Jersey, November, 8, 2023 – IFF’s and BASF’s Pharma Solutions divisions have joined forces in a collaboration to onboard IFF’s leading product brands in pharmaceutical excipients on BASF’s Virtual Pharma Assistant platform – ZoomLab™. The platform is a science-based digital tool designed to rapidly and accurately predict the best excipients needed for the development of new pharmaceutical formulations to help overcome formulation challenges.

The collaboration between IFF and BASF aligns with the companies’ shared values on customer-centricity and the goal to bring a seamless digital experience to more formulators worldwide. Powered by BASF’s proprietary algorithm, ZoomLab™ allows formulators to accelerate formulation design by predicting the most effective excipients to match a given active pharmaceutical ingredient. It also allows them to make customizations, offering a range of ingredients to choose from – including IFF’s renowned high-quality excipients.

In the first phase of the collaboration, IFF’s product line Avicel® microcrystalline cellulose (MCC) and super disintegrant Ac-Di-Sol® croscarmellose sodium will be available to users in ZoomLab™ Excipient Database and throughout the various ZoomLab™ modules. Formulators and ZoomLab™ users will benefit through this broadened access to excipients to solve their formulation challenges.

“Our collaboration with IFF aligns well with our commitment to provide exceptional value to our customers through our digital Virtual Pharma Assistants. Including IFF products within ZoomLab™ underlines our ambition to continuously develop ZoomLab™ into the leading industry platform giving users access to a broad range of excipients and make it even easier to create formulations quickly,” said Jeffrey DeAlmeida, senior vice president, BASF Pharma Solutions and Nutrition and Health, Americas. “We will continue to deepen our collaboration on ZoomLab™ in the future including more content and features for users.”

“At IFF, we apply a customer-centric approach to problem-solving throughout the drug development process. We are committed to being the partner our customers can count on, and now – thanks to our exciting collaboration with BASF on ZoomLab™ – we are helping even more customers innovate and overcome their formulation challenges,” said Angela Strzelecki, president, IFF Pharma Solutions. “The addition of our renowned ingredients into this platform enhances the ability of ZoomLab™ to predict the best formulations and accelerates the launch of more innovative products across the global pharmaceutical market which is good for manufacturers and patients around the world.”

To learn more about corporate premium, visit our new webpage.

About ZoomLab™

ZoomLab™ is a science-based digital tool that allows formulators to predict their next drug’s starting formulations and solve other formulation challenges. ZoomLab™ is available online. Learn more about ZoomLab™ on Zoomlab™ (

About BASF

At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. More than 111,000 employees in the BASF Group contribute to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio comprises six segments: Chemicals, Materials, Industrial Solutions, Surface Technologies, Nutrition & Care and Agricultural Solutions. BASF generated sales of €87.3 billion in 2022. BASF shares are traded on the stock exchange in Frankfurt (BAS) and as American Depositary Receipts (BASFY) in the United States. Further information at